Premier Inc., AstraZeneca work to reduce hospitalizations of patients with hyperkalemia

Bottle of pills on a conveyor belt

August 18, 2020 – Premier Inc. (Charlotte, NC) has reached a significant milestone in its partnership with AstraZeneca that is aimed at reducing hospitalizations among patients with hyperkalemia, which is characterized by higher-than-normal potassium levels. Premier Applied Sciences has implemented evidence-based care practices with nearly 370 hospitals across the U.S. designed to prevent patients with hyperkalemia from requiring treatment in the acute-care setting.

Together, Premier Applied Sciences and AstraZeneca have developed a protocol for monitoring and treating patients with hyperkalemia. The protocol includes the potential use of LOKELMA (sodium – zirconium cyclosilicate), a potassium binder indicated for the treatment of hyperkalemia in adults.

Hospitals participating in the partnership are eligible for discounts on LOKELMA from AstraZeneca. These evidence-based care practices allow hospitals to improve care delivery with an aim to reduce the risk for admissions and readmissions for patients with hyperkalemia.

Learn More

safe online pharmacy for viagra cheap kamagra oral jelly online